Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.

New data from researchers at MSK featured in the 2022 ASCO Annual Meeting press program and simultaneously published in The New England Journal of Medicine highlights a novel antibody-drug conjugate that doubled progression-free survival in HER2-low metastatic breast cancer.

Memorial Sloan Kettering Cancer Center (MSK) and New York Cancer & Blood Specialists (NYCBS), one of the fastest-growing community oncology practices in the nation, today announced plans to open a 39,000 sq ft facility in Brooklyn, New York, in early 2023.

Physicians and scientists from MSK will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2022 ASCO Annual Meeting, June 3–7 in Chicago.

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

By sequencing the entire genome of a tumor, the experimental test will go beyond standard testing for common cancers in adults.

Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation are proud to announce today that 13 distinguished MSK nurses and one nursing team were recognized with the 2022 Robbins Family Award for Nursing Excellence. During National Nurses Week (May 6 – 12), MSK recognizes outstanding nurses for exemplary service.

The Ralph Lauren Corporate Foundation announced today that it's providing $25 million in new grant funding to expand or establish five Ralph Lauren cancer centers, aimed at reducing disparities in cancer care and access across underserved communities. The funding will benefit institutions including the Memorial Sloan Kettering (MSK) Ralph Lauren Center in Harlem.

The Cycle for Survival community, along with founding partner, Equinox, achieves a historic fundraising milestone, fueling rare cancer research at Memorial Sloan Kettering.

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: